Technical Analysis for VTRS - Viatris Inc.

Grade Last Price % Change Price Change
F 13.91 2.35% 0.32
VTRS closed up 2.35 percent on Friday, March 5, 2021, on 1.17 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical VTRS trend table...

Date Alert Name Type % Chg
Slingshot Bearish Bearish Swing Setup 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Wide Bands Range Expansion 2.35%
Down 3 Days in a Row Weakness 2.35%
Down 4 Days in a Row Weakness 2.35%
Down 5 Days in a Row Weakness 2.35%
Oversold Stochastic Weakness 2.35%
Wide Bands Range Expansion 0.22%
Down 3 Days in a Row Weakness 0.22%
Older End-of-Day Signals for VTRS ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Viatris Inc. Description

Viatris Inc. is a new kind of healthcare company, empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway™. Formed in November 2020 through the combination of Mylan and Pfizer's Upjohn business, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, a growing portfolio of biosimilars and a variety of over-the-counter consumer products. With a global workforce of approximately 45,000, Viatris is headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India.


Classification

Sector: Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Keywords: Biotechnology Life Sciences Infectious Diseases Pharmaceutical Companies Biosimilar

Is VTRS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 19.24
52 Week Low 12.75
Average Volume 11,381,496
200-Day Moving Average 16.43
50-Day Moving Average 17.24
20-Day Moving Average 16.44
10-Day Moving Average 14.63
Average True Range 0.64
ADX 36.99
+DI 12.46
-DI 39.04
Chandelier Exit (Long, 3 ATRs ) 16.77
Chandelier Exit (Short, 3 ATRs ) 15.22
Upper Bollinger Band 20.19
Lower Bollinger Band 12.70
Percent B (%b) 0.16
BandWidth 45.55
MACD Line -1.03
MACD Signal Line -0.70
MACD Histogram -0.3359
Fundamentals Value
Market Cap 7.53 Billion
Num Shares 542 Million
EPS
Price-to-Sales 0.78
Price-to-Book 1.66
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 14.86
Resistance 3 (R3) 14.78 14.38 14.70
Resistance 2 (R2) 14.38 14.14 14.42 14.64
Resistance 1 (R1) 14.15 13.99 14.27 14.23 14.59
Pivot Point 13.75 13.75 13.81 13.79 13.75
Support 1 (S1) 13.52 13.51 13.64 13.60 13.23
Support 2 (S2) 13.12 13.36 13.16 13.18
Support 3 (S3) 12.89 13.12 13.12
Support 4 (S4) 12.97